Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis

Ja Kyung Kim, Soo Jeong Kim, Yuri Kim, Yong Eun Chung, Young Nyun Park, Hyun Ok Kim, Jin Seok Kim, Mi Suk Park, Isao Sakaida, Do Young Kim, Jung Il Lee, Sang Hoon Ahn, Kwan Sik Lee, Kwang Hyub Han

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Although several human clinical trials using various bone marrow-derived cell types for cirrhotic or decompensated patients have reported a short-term benefit, long-term follow-up data are limited. We analyzed the long-term clinical outcomes of autologous bone marrow cell infusion (ABMI) for decompensated liver cirrhosis (LC). Patients enrolled in a pilot single-armed ABMI study were followed up more than 5 years. Bone marrow-derived mononuclear cells (BM-MNCs) from decompensated LC were harvested and after processing were infused into a peripheral vein. The laboratory test results and long-term clinical course including liver transplantation (LT), development of cancer, cause of death, and survival after ABMI were analyzed. Nineteen patients were followed up for a median of 66 months after ABMI. Liver function, including serum levels of albumin and Child-Pugh (CP) score, was improved at the 1-year follow-up. Liver volume was significantly greater, cirrhosis was sustained, and collagen content was decreased at the 6-month follow-up. Five years after ABMI, five patients (26.3%) maintained CP class A without LT or death, and five patients (26.3%) had undergone elective LT. Hepatocellular carcinoma (HCC) occurred in five patients (26.3%), and lymphoma and colon cancer occurred in one patient each. Three patients (15.8%) were lost to follow-up at months 22, 31, and 33, respectively, but maintained CP class A until their last follow-up. Five patients expired due to infection. While improved liver function was maintained in some patients for more than 5 years after ABMI, other patients developed HCC. Further studies of long-term follow-up cohorts after cell therapy for LC are warranted.

Original languageEnglish
Pages (from-to)1059-1066
Number of pages8
JournalCell transplantation
Issue number6
Publication statusPublished - 2017

Bibliographical note

Publisher Copyright:
© 2017 Cognizant, LLC.

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Cell Biology
  • Transplantation


Dive into the research topics of 'Long-term follow-up of patients after autologous bone marrow cell infusion for decompensated liver cirrhosis'. Together they form a unique fingerprint.

Cite this